Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Fineline Cube Apr 20, 2026
Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Fineline Cube Apr 20, 2026
Company Drug

Astellas Resubmits FDA Application for Vyloy as Treatment for CLDN18.2-Positive Cancer

Fineline Cube Jun 3, 2024

Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has resubmitted its first-in-class anti-CLDN18.2 biologic...

Company Drug

Simcere Pharma’s Suvemcitug Shows Positive Results in Platinum-Resistant Ovarian Cancer Study

Fineline Cube Jun 3, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has presented updated data...

Company Drug

Ascentage Pharma’s APG-2449 Shows Positive Results in ROS1 and ALK Positive NSCLC at ASCO 2024

Fineline Cube Jun 3, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in Suzhou, has announced a wall poster...

Company Drug

Jacobio Pharma’s KRAS G12C Inhibitor Combo Shows Promising Results in NSCLC at ASCO 2024

Fineline Cube Jun 3, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, presented updated data at the...

Policy / Regulatory

NMPA Announces Digitalization of Medical Device Regulatory Documents

Fineline Cube Jun 3, 2024

The National Medical Products Administration (NMPA) has announced a transition to digitalize regulatory documentation for...

Policy / Regulatory

China’s NHSA Launches New Procedures for Drug Catalogue Attribution Identification

Fineline Cube Jun 3, 2024

The National Healthcare Security Administration (NHSA) has issued the “Procedures for Identification of Drug and...

Company Drug

Innovent Biologics Presents Clinical Data for Pipeline Candidates at ASCO 2024

Fineline Cube Jun 3, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, presented updates on several...

Company Medical Device

Andon Health’s COVID-19 Trio Test Kit and OTC Antigen Test Win FDA Approval

Fineline Cube Jun 3, 2024

Andon Health Co., Ltd (SHE: 002432), a healthcare company based in China, has announced that...

Company

Nanjing Kingfriend Biochemical Gets FDA Nod for Dacarbazine Manufacture at Sagent Facility

Fineline Cube Jun 3, 2024

Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced that...

Company Drug

Gilead’s Trodelvy Misses Overall Survival Endpoint in Late-Stage Urothelial Cancer Study

Fineline Cube Jun 3, 2024

Gilead (NASDAQ: GILD) has announced that a late-stage study for its antibody-drug conjugate (ADC) Trodelvy...

Company Drug

Chipscreen’s Chidamide in Sight of Breakthrough Therapy Designation in China for MSS/pMMR Colorectal Cancer

Fineline Cube Jun 3, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...

Company Drug

Simcere Pharma’s Anti-Insomnia Drug Daridorexant Meets Primary Endpoint in Phase III Clinical Trial

Fineline Cube Jun 3, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced topline results from a Phase III...

Company Drug

ImmuneOnco Receives NMPA Approval for Phase III Clinical Trial of Timdarpacept in CMML

Fineline Cube Jun 3, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Receives Positive CHMP Opinion for NSCLC Treatment in Europe

Fineline Cube Jun 3, 2024

CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced that it has...

Company Deals

MSD to Acquire Ophthalmology Specialist Eyebiotech in a Deal Valued Up to USD 3 Billion

Fineline Cube May 31, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into an agreement to acquire UK-based...

Company Drug

FDA Extends Indication for BMS’ CAR-T Therapy Breyanzi to Include Relapsed MCL in Adults

Fineline Cube May 31, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Drug

Novartis Halts Development of KRAS Inhibitor Opnurasib Due to Competitive Market

Fineline Cube May 31, 2024

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase...

Company Drug

Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain

Fineline Cube May 31, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...

Company Deals

TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China

Fineline Cube May 31, 2024

Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered...

Company Deals

Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China

Fineline Cube May 31, 2024

Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in...

Posts pagination

1 … 339 340 341 … 654

Recent updates

  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
  • Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors
  • Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium
  • Eli Lilly Launches Omvoh (Mirikizumab) in China for Inflammatory Bowel Disease – IL-23p19 Antagonist Targets Ulcerative Colitis and Crohn’s Disease Following February Approval
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.